Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Limited announced the issuance and conversion of unquoted equity securities, with a total of 83,853 ordinary fully paid securities being issued on specified dates in 2023. This move could impact the company’s financial structure and shareholder value, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services across Australia. The company is known for its comprehensive range of diagnostic services, catering to both individual patients and healthcare providers.
Average Trading Volume: 1,011,517
Technical Sentiment Signal: Sell
Current Market Cap: A$524.2M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.